What's in AVET LIFESCIENCES's pipeline?

AVET LIFESCIENCES has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with AVET LIFESCIENCES's portfolio?

Top competitors by shared drug class: , Apotex, Baxter, Eisai, Leadiant Biosci Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/avet-lifesciences.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

AVET LIFESCIENCES — Portfolio Competitive Intelligence Brief

AVET LIFESCIENCES pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Gliadel	CARMUSTINE	marketed	Alkylating Drug	Glutathione reductase, mitochondrial	Oncology	1977-01-01

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Apotex · 1 shared drug class
Baxter · 1 shared drug class
Eisai · 1 shared drug class
Leadiant Biosci Inc · 1 shared drug class
Oncopeptides Ab · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AVET LIFESCIENCES:

Cite this brief

Drug Landscape (2026). AVET LIFESCIENCES — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/avet-lifesciences. Accessed 2026-05-16.